title: Rosiglitazone reduces ischaemia-reperfusion injury in patients with the metabolic syndrome.
authors.affiliation: Department of Pharmacology-Toxicology, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Evidence Based Practice and Institute for Genetic and Metabolic Disease, PO Box 9101, 6500 HB Nijmegen, The Netherlands. a.rennings@pharmtox.umcn.nl
authors.forename: Alexander J
authors.initials: AJ
authors.lastname: Rennings
authors.forename: Patrick
authors.initials: P
authors.lastname: Meijer
authors.forename: Dominique J
authors.initials: DJ
authors.lastname: van Uden
authors.forename: Cees J
authors.initials: CJ
authors.lastname: Tack
authors.forename: Paul
authors.initials: P
authors.lastname: Smits
authors.forename: Otto C
authors.initials: OC
authors.lastname: Boerman
authors.forename: Wim J
authors.initials: WJ
authors.lastname: Oyen
authors.forename: Gerard A
authors.initials: GA
authors.lastname: Rongen
mesh_terms: D004311:Double-Blind Method; D005542:Forearm / Q000098:blood supply; D006801:Humans; D007333:Insulin Resistance; D007511:Ischemia / Q000000981:diagnostic imaging; D024821:Metabolic Syndrome / Q000150:complications*; D018482:Muscle, Skeletal / Q000098:blood supply; D011877:Radionuclide Imaging; D015427:Reperfusion Injury / Q000517:prevention & control*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D045162:Thiazolidinediones; D014665:Vasodilator Agents; D000077154:Rosiglitazone